Clover Biopharmaceuticals, Ltd. announced the appointment of Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to the company's Board of Directors. Dr. Ambrosino is a renowned scientific leader for vaccine development and a current member of Clover's Vaccine Scientific Advisory Board. Until November 2019, she served as Chief Executive Officer at Nosocomial Vaccine Corporation, where she led the collaborative discovery and development of a gram-negative vaccine for hospital-acquired infections.

Prior to that, as the first Chief Executive Officer of MassBiologics, she recruited and led the scientific team that discovered multiple monoclonal antibodies targeting infectious disease pathogens, with three products reaching late-stage development and two now commercially available. Dr. Ambrosino was also an associate professor of pediatrics at the Dana-Farber Cancer Institute and Children's Hospital, Harvard Medical School. At Harvard Medical School she was a National Institutes of Health-funded researcher.

Dr. Clemens has held executive positions in several leading multinational corporations, such as GSK, Novartis Vaccines, and Takeda, and has developed and brought to licensure more than 25 different vaccines globally. In addition to founding and chairing Clover's Vaccine Scientific Advisory Board since its inception in 2020, he is currently a member of the Board of Trustees of the International Vaccine Institute (IVI), a leading global vaccinology organization initiated by the United Nations Development Programme, a Member of the Selection Committee of Global Health Innovative Technology (GHIT) Fund from Japan, and an external Scientific Advisor to the Bill & Melinda Gates Foundation. He is the author of more than 190 publications and 250 presentations in the fields of vaccines, immunization, and tropical medicine.